Wockhardt secures US FDA approval for antibiotic Zaynich

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mrkbf30
via IFTTT

Read More

Molecule glue drugs shake up cancer care, draw big money

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l5uhT37
via IFTTT

Read More

Lincoln Pharmaceuticals posts Rs 11.63 crore profit for Q4

Lincoln Pharmaceuticals announced a slight profit rise for the fourth quarter ending March 31, 2026. Full fiscal year 2025-26 saw over 6 percent growth in consolidated net profit. Revenue from operations also increased year-on-year. The company's board recommended an 18 percent dividend. Lincoln Pharmaceuticals targets Rs 1,000 crore revenue in three years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/76Rj9yd
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6aAjqyO
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Goup CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3WLvRrg
via IFTTT

Read More

Zydus Therapeutics' saroglitazar drug granted priority review by US FDA

Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver disease. The company plans to launch saroglitazar in the US in the fourth quarter of fiscal year 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gNGJ9PZ
via IFTTT

Read More

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with chronic hepatitis B.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3KpX2D
via IFTTT

Read More